Roche chair slams US tariffs as “blackmail" and warns rising US-China protectionism is top geopolitical risk.
Schwan identified protectionism by the United States and China as the firm's biggest geopolitical worry.
Keystone-SDA
The Swiss pharmaceutical company Roche is increasingly concerned by protectionism in the United States and China. At the Swiss Economic Forum (SEF) in Interlaken on Thursday, Roche Chair Severin Schwan hit out at US tariff policies, likening them to "blackmail".
Generated with artificial intelligence.
This content was published on
Interpharma warns Switzerland may face a US Section 301 trade probe targeting drug pricing, threatening $35.5 billion in pharma…
The US may open a trade investigation into Switzerland's pharmaceutical industry, threatening tariffs on $35.5 billion in imports…
In an interview with CNBC on Tuesday, Trump said “We have a $41 billion deficit" with Switzerland. It was not immediately clear…
I vertici di Novartis e Roche hanno incontrato il governo svizzero per discutere della situazione dell'industria farmaceutica…
Currency effects weighed on the Swiss drugmaker's first-quarter earnings
Karin Keller-Sutter accused of mishandling talks as shares dive after Switzerland hit with 39% tariff
